Search research articles
Contact Us
Filters
Showing results (71-80 of 88) with videos related to
Page
of 9
Sort By:
Leukemia
|
October 24, 2013
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
A F List, J M Bennett, M A Sekeres, et al.
Leukemia
|
December 10, 2015
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
A F List, J M Bennett, M A Sekeres, et al.
Transplantation
|
April 1, 1990
Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low-dose total-lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy
R E Champlin, W G Ho, S D Nimer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2007
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
C H Moskowitz, P A Hamlin, J Gabrilove, et al.
Bone Marrow Transplantation
|
June 25, 2008
High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease
H Hassoun, C Flombaum, V D D'Agati, et al.
Oncogene
|
April 15, 2008
Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1
N Kalakonda, W Fischle, P Boccuni, et al.
Bone Marrow Transplantation
|
April 27, 1999
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma
C H Moskowitz, S D Nimer, J R Glassman, et al.
Blood
|
September 26, 2000
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis
T Kewalramani, A D Zelenetz, E E Hedrick, et al.
Blood
|
September 6, 2001
Myelodysplastic syndromes standardized response criteria: further definition
B D Cheson, J M Bennett, H Kantarjian, et al.
Cancer Research
|
July 14, 1998
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract
B Pasche, Y Luo, P H Rao, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 88) with videos related to
Sort By:
Page
of 9
Leukemia
|
October 24, 2013
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
A F List, J M Bennett, M A Sekeres, et al.
Leukemia
|
December 10, 2015
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
A F List, J M Bennett, M A Sekeres, et al.
Transplantation
|
April 1, 1990
Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low-dose total-lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy
R E Champlin, W G Ho, S D Nimer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2007
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
C H Moskowitz, P A Hamlin, J Gabrilove, et al.
Bone Marrow Transplantation
|
June 25, 2008
High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease
H Hassoun, C Flombaum, V D D'Agati, et al.
Oncogene
|
April 15, 2008
Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1
N Kalakonda, W Fischle, P Boccuni, et al.
Bone Marrow Transplantation
|
April 27, 1999
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma
C H Moskowitz, S D Nimer, J R Glassman, et al.
Blood
|
September 26, 2000
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis
T Kewalramani, A D Zelenetz, E E Hedrick, et al.
Blood
|
September 6, 2001
Myelodysplastic syndromes standardized response criteria: further definition
B D Cheson, J M Bennett, H Kantarjian, et al.
Cancer Research
|
July 14, 1998
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract
B Pasche, Y Luo, P H Rao, et al.
Page
of 9